GlassScriptPhysician profile
Melissa Andrade
NPI 1801339163
$6,270.58
in general payments reported to CMS, 2019-2025
21 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $313 · 2023: $2,335 · 2024: $1,788 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,501 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,500.54 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,505.22 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $767.32 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $730.64 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $717.78 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $477.08 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $294.17 | 2025 | Fanapt |
| Lundbeck LLC | $265.99 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.54 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $206.63 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $177.72 | 2021-2024 | Trintellix |
| Noven Therapeutics, LLC | $175.82 | 2023-2024 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $156.33 | 2023-2024 | Auvelity |
| Alkermes, INC. | $138.47 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Noven Pharmaceuticals, INC. | $107.59 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $102.25 | 2023-2024 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $69.07 | 2023-2024 | Perseris |
| Collegium Pharmaceutical, INC. | $41.30 | 2025 | Jornay Pm |
| Corium, LLC | $34.08 | 2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $27.21 | 2021 | |
| Lilly USA, LLC | $24.79 | 2022 | |
| Btg International INC. | $17.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Andrade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.